Journal Club: Randomized phase III study 306: Adjunctive perampanel for refractory partial-onset seizures

A working understanding of antiepileptic drug development, critical appraisal of drug trial design, and interpretation of study results are fundamental for the neurologist and epileptologist, to incorporate newer anticonvulsant medications into clinical practice. In this Journal Club, we evaluate a phase III study by Krauss et al.1 that demonstrates efficacy and safety of adjunctive perampanel for refractory partial-onset seizures.